Abstract

Phenome-wide association studies (PheWAS) facilitate the discovery of associations between a single genetic variant with multiple phenotypes. For variants which impact a specific protein, this can help identify additional therapeutic indications or on-target side effects of intervening on that protein. However, PheWAS is restricted by an inability to distinguish confounding due to linkage disequilibrium (LD) from true pleiotropy. Here we describe CoPheScan (Coloc adapted Phenome-wide Scan), a Bayesian approach that enables an intuitive and systematic exploration of causal associations while simultaneously addressing LD confounding. We demonstrate its performance through simulation, showing considerably better control of false positive rates than a conventional approach not accounting for LD. We used CoPheScan to perform PheWAS of protein-truncating variants and fine-mapped variants from disease and pQTL studies, in 2275 disease phenotypes from the UK Biobank. Our results identify the complexity of known pleiotropic genes such as APOE, and suggest a new causal role for TGM3 in skin cancer.

Understanding pleiotropic genetic associations across multiple phenotypes, which could lead to understanding of common disease mechanisms or therapeutics. Here, the authors present CoPheScan, a Bayesian method for PheWAS which detects genetic associations with multiple phenotypes and distinguishes pleiotropy from LD-confounding.

Details

Title
CoPheScan: phenome-wide association studies accounting for linkage disequilibrium
Author
Manipur, Ichcha 1   VIAFID ORCID Logo  ; Reales, Guillermo 1   VIAFID ORCID Logo  ; Sul, Jae Hoon 2 ; Shin, Myung Kyun 2   VIAFID ORCID Logo  ; Longerich, Simonne 2 ; Cortes, Adrian 3 ; Wallace, Chris 4   VIAFID ORCID Logo 

 University of Cambridge, Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Jeffrey Cheah Biomedical Centre, Cambridge Biomedical Campus, Cambridge, UK (GRID:grid.5335.0) (ISNI:0000 0001 2188 5934); University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Department of Medicine, Cambridge, UK (GRID:grid.5335.0) (ISNI:0000 0001 2188 5934) 
 Inc., Merck & Co., Rahway, USA (GRID:grid.417993.1) (ISNI:0000 0001 2260 0793) 
 GSK, Human Genetics and Genomics, Heidelberg, Germany (GRID:grid.420105.2) (ISNI:0000 0004 0609 8483) 
 University of Cambridge, Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Jeffrey Cheah Biomedical Centre, Cambridge Biomedical Campus, Cambridge, UK (GRID:grid.5335.0) (ISNI:0000 0001 2188 5934); University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Department of Medicine, Cambridge, UK (GRID:grid.5335.0) (ISNI:0000 0001 2188 5934); University of Cambridge, MRC Biostatistics Unit, Cambridge, UK (GRID:grid.5335.0) (ISNI:0000000121885934) 
Pages
5862
Publication year
2024
Publication date
2024
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3079594105
Copyright
© The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.